Ignite Creation Date:
2025-12-25 @ 2:06 AM
Ignite Modification Date:
2025-12-26 @ 4:26 AM
Study NCT ID:
NCT04485260
Status:
UNKNOWN
Last Update Posted:
2022-05-09
First Post:
2020-07-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
Sponsor:
Kartos Therapeutics, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-01-28
Start Date Type:
ACTUAL
Primary Completion Date:
2022-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-10
Completion Date Type:
ESTIMATED
First Submit Date:
2020-07-21
First Submit QC Date:
None
Study First Post Date:
2020-07-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-05-05
Last Update Post Date:
2022-05-09
Last Update Post Date Type:
ACTUAL